Risperidone extended release - Luye Pharma Group

Drug Profile

Risperidone extended release - Luye Pharma Group

Alternative Names: LY-03004; Risperidone ER microspheres - Luye Pharma Group

Latest Information Update: 08 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Luye Pharma Group
  • Class Antineoplastics; Antipsychotics; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Bipolar disorders; Schizophrenia

Most Recent Events

  • 26 Feb 2018 Luye Pharma has patent protection for risperidone extended release microspheres in USA, China, Europe, Japan and South Korea
  • 26 Feb 2018 The US FDA waives the paediatric clinical trials required for the submission of NDA in USA
  • 08 Feb 2018 Clinical trials in Schizophrenia and Bipolar disorders in China, Europe and Japan (IM) before February 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top